These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25156438)

  • 1. Successful Treatment of Hepatitis B Virus-associated Membranous Nephropathy with Entecavir and Immunosuppressive Agents.
    Ochi A; Ishimura E; Ichii M; Ohno Y; Nakatani S; Kobayashi I; Shima H; Tsuda A; Shidara K; Mori K; Tamori A; Inaba M
    Nephrology (Carlton); 2014 Sep; 19(9):595-6. PubMed ID: 25156438
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis B virus-related membranous nephropathy treated with entecavir.
    Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
    Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of sulodexide might be associated with inhibition of complement system in hepatitis B virus-associated membranous nephropathy: An inspiration from a pilot trial.
    Yang Y; Ma L; Wang C; Kong D; Wang Y; Mei C
    Eur J Intern Med; 2016 Jul; 32():96-104. PubMed ID: 27160380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Use of Entecavir in Hepatitis B-associated Membranous Nephropathy.
    Mahajan V; D'Cruz S; Nada R; Sachdev A
    J Trop Pediatr; 2018 Jun; 64(3):249-252. PubMed ID: 28977667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term lamivudine therapy in hepatitis B-associated membranous nephropathy?
    Ng YY; Yang WC; Lee ST
    Kidney Int; 2006 Feb; 69(4):776. PubMed ID: 16518335
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of occult hepatitis B virus infection related membranous nephropathy after entecavir therapy.
    Xiong QF; Zhong YD; Hu ZL; Yang YF
    Acta Clin Belg; 2015 Jun; 70(3):223-5. PubMed ID: 25510219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B-related membranous nephropathy should be treated with a specific anti-viral agent.
    Tang S; Lai KN
    Kidney Int; 2006 Aug; 70(4):818. PubMed ID: 16900222
    [No Abstract]   [Full Text] [Related]  

  • 8. [New advances in the treatment of chronic hepatitis B: position of entecavir].
    Olaso V
    Rev Esp Quimioter; 2007 Sep; 20(3):259-60. PubMed ID: 18080023
    [No Abstract]   [Full Text] [Related]  

  • 9. A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy.
    Yang Y; Ma YP; Chen DP; Zhuo L; Li WG
    PLoS One; 2016; 11(9):e0160437. PubMed ID: 27598699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy.
    Yang YF; Xiong QF; Zhao W; Zhong YD
    Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):e89-92. PubMed ID: 22572521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.
    Watanabe M; Shibuya A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Koizumi W
    Eur J Intern Med; 2010 Aug; 21(4):333-7. PubMed ID: 20603047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of entecavir for the treatment of complex forms of hepatitis B.
    Sacco R
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1333-43. PubMed ID: 24867511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Management of De Novo Acute Hepatitis B Virus Infection With Entecavir in a Living-Donor Liver Transplant Patient.
    Akbulut S; Harputluoglu M; Yilmaz S
    Exp Clin Transplant; 2018 Oct; 16(5):635-637. PubMed ID: 29790455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-hepatitis B virus drugs].
    Minami M
    Nihon Rinsho; 2012 Apr; 70(4):609-13. PubMed ID: 22568141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hepatitis B virus-associated nephropathy.
    Elewa U; Sandri AM; Kim WR; Fervenza FC
    Nephron Clin Pract; 2011; 119(1):c41-9; discussion c49. PubMed ID: 21677438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
    Reddy KR; Beavers KL; Hammond SP; Lim JK; Falck-Ytter YT;
    Gastroenterology; 2015 Jan; 148(1):215-9; quiz e16-7. PubMed ID: 25447850
    [No Abstract]   [Full Text] [Related]  

  • 17. Transformation of hepatitis B virus-related membranous glomerulonephritis to crescentic form.
    Taskapan H; Oymak O; Dogukan A; Ozbakir O; Utas C
    Clin Nephrol; 2000 Aug; 54(2):161-3. PubMed ID: 10968695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir and intermittent etanercept therapy in a patient with concurrent hepatitis B virus infection and psoriasis.
    Babino G; Esposito M; Mazzotta A; Chimenti S; Giunta A
    Acta Derm Venereol; 2013 May; 93(3):373-4. PubMed ID: 23147755
    [No Abstract]   [Full Text] [Related]  

  • 19. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.
    Perrillo RP; Gish R; Falck-Ytter YT
    Gastroenterology; 2015 Jan; 148(1):221-244.e3. PubMed ID: 25447852
    [No Abstract]   [Full Text] [Related]  

  • 20. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
    Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.